<div id="readability-page-1"><div> <div> Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. , /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share. If you are a XOMA shareholder, click here to learn more about your rights and options. Organon &amp; Co. (NYSE: OGN)'s sale to Sun Pharmaceutical Industries Limited for $14.00 per share. If you are an Organon shareholder, click here to learn more about your legal rights and options. Veris Residential, Inc. (NYSE: VRE)'s sale to an investor consortium led by Affinius Capital in partnership with Vista Hill Partners for $19.00 per share. If you are a Veris shareholder, click here to learn more about your rights and options. On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. One World Trade Center 85th Floor New York, NY 10007 (212) 763-0060 [email protected] [email protected] https://www.halpersadeh.com SOURCE Halper Sadeh LLP <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9Tlk2MDIwOSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQxNzI1UFJfTkVXU19VU1BSX19fX19OWTYwMjA5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9Tlk2MDIwOSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQxNzI1UFJfTkVXU19VU1BSX19fX19OWTYwMjA5"/></div> </div></div>

XOMA

Halper Sadeh LLC is investigating XOMA, Organon & Co., and Veris Residential for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders in proposed transactions. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on XOMA's sale for $39.00 per share, Organon's sale for $14.00 per share, and Veris's sale for $19.00 per share, with the firm seeking increased consideration and disclosures on behalf of shareholders.

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?